REDWOOD CITY, Calif., Sept. 18 /PRNewswire/ -- Ingenuity Systems, the leading provider of solutions to explore, analyze, and interpret scientific literature and data, is pleased to announce its membership in the Biomarkers Consortium, a major public-private biomedical research partnership created to discover, develop, and qualify new biological markers to support new drug development, preventive medicine, and medical diagnostics.
The founding members of the Consortium include the Foundation for the National Institutes of Health (FNIH), National Institutes of Health (NIH), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS); and the Pharmaceutical Research and Manufacturers of America (PhRMA).
"We are pleased to join the Biomarkers Consortium and to have the opportunity to participate in an evolving dialog with key thought leaders from top research organizations and agencies world-wide," stated Art Okamoto, Senior Product Manager at Ingenuity. "We are excited about the prospects offered by the Biomarkers Consortium, and hope to contribute to the development and accessibility of biomarker research in the scientific community."
Ingenuity is committed to helping life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity has recently launched IPA-Biomarker(TM) to help researchers identify and prioritize biomarker candidates based on key biological characteristics. Ingenuity's technology supports the Consortium's goal of advancing biomarker research by linking potential markers to a disease or biological process of interest.
About Ingenuity Systems(R)
Ingenuity Systems enables researchers to model, analyze, and understand
complex biological and chemical systems foundational to human health and
disease. All of Ingenuity's products and services have one common goal --
to provide relevant context and understanding to life science researchers.
|SOURCE Ingenuity Systems|
Copyright©2007 PR Newswire.
All rights reserved